6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03412513 (ClinicalTrials.gov) | July 17, 2017 | 21/1/2018 | Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease | Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial | Overactive Bladder;Parkinson Disease | Drug: Mirabegron;Drug: Placebo | Seoul National University Hospital | NULL | Unknown status | 40 Years | 80 Years | All | 144 | Phase 4 | Korea, Republic of |
2 | NCT02536976 (ClinicalTrials.gov) | December 2015 | 28/8/2015 | Mirabegron in Parkinson Disease and Impaired Cognition | A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition | Parkinson Disease;Overactive Bladder;Impaired Cognition | Drug: mirabegron;Drug: Placebo | HealthPartners Institute | NULL | Completed | 25 Years | 80 Years | All | 7 | Phase 4 | United States |
3 | NCT02092181 (ClinicalTrials.gov) | March 2014 | 7/3/2014 | A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) | A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO) | Parkinsons Disease | Drug: Mirabegron;Drug: Placebo | Daniel Burdick, MD | Astellas Pharma US, Inc. | Completed | 30 Years | 85 Years | All | 30 | Phase 4 | United States |